Granted Patent
B2
US 8,362,224 · App. 12/520,515 · Granted Jan 29, 2013
Screening for CD93 (C1qRp)-associated polymorphism(S) in the diagnosis, prevention and treatment of autoimmune diseases
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE).
Claims (4)
1. An isolated nucleic acid molecule encoding a mutated CD93 protein consisting of the amino acid sequence set forth in SEQ ID NO: 4.
2. The isolated nucleic acid of claim 1 , wherein said nucleic acid has a nucleotide sequence consisting of the nucleic acid sequence set forth in SEQ ID NO: 3.
3. A vector comprising the nucleic acid molecule of claim 1 .
4. A vector comprising the nucleic acid molecule of claim 1 , operably linked to a transcriptional promoter.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Dec 20, 2018
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048965/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 30, 2009
From: NOORCHASHM, HOOMAN; NAJI, ALI
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 023718/0649 →
Continuity (3)
Provisional Application
60875556
· Dec 19, 2006
Provisional Application
60905573
· Mar 8, 2007